SMTL ID : 9iut.1 (1 other biounit)

Crystal structure of cancer-specific anti-HER2 antibody H2Mab-250 in complex with epitope peptide

Coordinates

PDB Format Compare

Method

X-RAY DIFFRACTION 2.09 Å

Oligo State

hetero-1-1-mer

Ligands

1 x MET- PRO- ILE- TRP- LYS- PHE- PRO- ASP: H2Mab-250 epitope peptide(Non-covalent)

MET-PRO-ILE-TRP-LYS-PHE-PRO-ASP.1: 26 residues within 4Å: Chain A: G.35, M.36, S.37, T.52, I.53, N.54, G.59, T.60, Y.61, P.101, G.102, L.103, L.104 Chain B: D.33, R.37, Y.39, N.41, R.53, Y.56, L.57, W.96, Q.97, G.98, T.99, F.101, Q.103 10 PLIP interactions: 5 interactions with chain A, 5 interactions with chain B Hydrophobic interactions: A:T.52, A:Y.61, A:P.101, A:L.104, B:Y.56, B:Y.56, B:W.96 Hydrogen bonds: A:N.54, B:T.99, B:Q.103

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Hosking, M.P. et al., Preferential tumor targeting of HER2 by iPSC-derived CAR-T cells engineered to overcome multiple barriers to solid tumor efficacy. Cell Stem Cell (2025)

Release Date

2025-06-04

Peptides

H2Mab-250 VH(S112C)-SARAH: A
H2Mab-250 VL-SARAH(S37C): B

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
A

B
B

H2Mab-250 VH(S112C)-SARAH

H2Mab-250 VL-SARAH(S37C)

Related Entries With Identical Sequence